SCP Vitalife Partners
Venture capitalTel Aviv · Seed–Late Stage · 11 people tracked
Also known as SCP VITALIFE MANAGEMENT COMPANY, LLC
Investment thesis
SCP Vitalife invests in life science startups in Israel and the U.S. that develop breakthrough products addressing current medical needs and protected by strong intellectual property. The firm has made more than 30 investments across two funds. Its team consists of professionals with experience as entrepreneurs, senior operating executives, clinical practitioners and technologists, and it provides hands-on support to portfolio companies by leveraging strategic partner relationships to help build successful businesses.
Source: firm website, verified Aug 11, 2026.
Team · 11 people
from the firm's website & public directories
What they invest in
from 11 of 20 portfolio companiesBiotech ×7Healthtech ×5Medical Devices ×5Digital Health ×1EdTech ×1Enterprise Software ×1Media & Entertainment ×1SaaS ×1
HQs:United States×5Israel×2
Investments · 20 tracked
founders shown can be your intro pathBy year:2026 · 12021 · 12020 · 12015 · 32014 · 17 dated
BiotechMarlborough, US
Charles Remsberg(Executive Officer)Larry Jasinski(Executive Officer, Director)Michael Lawless(Executive Officer)Almog Adar(Executive Officer)Jeannine Lynch(Executive Officer)Hadar Levy(Director)
Board seatWayne B. WeismanJeff Dykan· per SEC Form D · $8.8M raise · filed Jul 2020
Glaukos develops surgical and pharmaceutical therapies for ophthalmic diseases including glaucoma, corneal health, and retinal disease.
BiotechHealthtechMedical DevicesWaltham, US
Jason Hong(Director)David F. Muller(Executive Officer, Director)Robert Palmisano(Director)Philip J. Ferneau(Director)M. Carl Johnson, III(Director)David Berry(Director)
Board seatJeff Dykan· per SEC Form D
Echo360 provides learning engagement and analytics software to educational institutions and organizations.
EdTechEnterprise SoftwareSaaSReston, US
Frederick G.I. Singer(Executive Officer, Director)Jon Patty(Director)Rohit K. Seth(Director)Janet Hill(Director)Evan Morgan(Director)Anthony Abate(Executive Officer)
Board seatWayne B. Weisman· per SEC Form D · $7.5M raise · filed Jan 2016
Ivenix makes an intelligent infusion pump system for hospital settings that delivers intravenous medications to patients while incorporating safeguards to reduce medication errors.
BiotechHealthtechMedical DevicesAmesbury, US
John M. Douglass(Director)John Sokolowski(Executive Officer)John K. Clarke(Director)Jesse Ambrosina(Executive Officer)Colin J. Foster(Director)Darrell J. Crate(Director)
Board seatWayne B. Weisman· per SEC Form D
Specialty biopharmaceutical company developing differentiated prescription drugs for analgesia, anesthesia, sedation, and chronic pain management.
BiotechMalvern, US
Gerri A. Henwood(Executive Officer)
Board seatAbraham LudomirskiWayne B. WeismanWinston J. Churchill· per SEC Form D
Developing innovative biodegradable hydrogels for local repair of damaged cartilage and bone with unique in-vivo biodegradation profiles.
BiotechHerzliya
Galit Reske(Executive Officer)Arie Gordashnikov(Executive Officer)Susan Alpert(Director)Pini Ben-Elazar(Director)Keith Valentine(Director)Efraim Cohen-Arazi(Director)
Board seatJeff Dykan· per SEC Form D
Applies electro-optic infrared technology for non-contact pharmacological tests including counterfeit drug identification and pharmaceutical quality assurance.
Endospan develops endovascular stent graft systems, including the NEXUS Multi-Branch Aortic Arch Stent Graft System, for repairing aortic aneurysms and dissections in patients whose anatomy is unsuitable for traditional EVAR/TEVAR therapy.
HealthtechMedical Devices
Kevin Mayberry(Chief Executive Officer)Gadi Divald(Chief Financial Officer)
Cell therapy company focused on dermal-based regenerative therapy with proprietary scalable cell-manufacturing technology.
Biopharmaceutical company developing novel therapeutics for neurological diseases, initially targeting Parkinson's disease with potential disease modification.
Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.
Media & Entertainment
Commercializing CE-marked and FDA-cleared surgical devices for gastro-intestinal surgery using Nitinol-based products for natural tissue closure.
Developed an innovative automated clinical in-vitro diagnostic system providing real-time pathogen detection and identification without reagents.
BiotechRehovot
Ellen Cunniff(Executive Officer)Jonathan Gurfinkel(Executive Officer, Director)Eduard J. Ludwig(Director)Meir Hadar(Director)Gal Ingber(Executive Officer)Zvika Blutstein(Executive Officer)
Regentis Biomaterials develops regenerative medicine products for tissue repair, focused on orthopedic cartilage and bone treatments through its Gelrin degradable hydrogel platform.
BiotechHealthtechMedical Devices
Developing a non-invasive device for monitoring congestive heart failure through continuous measurement of pulmonary congestion parameters.
Developing a technology platform for orthopedics featuring a minimally invasive, motion-preserving interspinous spacer to treat low back and leg pain.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioLifewardNASDAQ: LFWD
Portfolio news
latest coverage across their companiesLifeward · ng.investing.com · Jul 7, 2026
Ivenix · trysignalbase.com · Mar 25, 2026
Echo 360 · marketbrief.edweek.org · May 22, 2025
Fund performance · per public LP disclosures · 3
as of Dec 2024| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| SCP Vitalife Partners II FundLPs: New York City Employees' Retirement System, New York City Police Pension Fund, New York City Fire Department Pension Fund | 2007 | — | -14.2% | 0.14x | 0.00x |
| SCP Vitalife Partners II, L.P.LPs: New York City Police Pension Fund, Teachers' Retirement System of the City of New York | 2007 | — | -17.7% | 0.07x | 0.07x |
| SCP Vitalife Partners Il FundLPs: New York City Fire Department Pension Fund | 2007 | — | -14.0% | 0.14x | 0.00x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does SCP Vitalife Partners invest at?
- SCP Vitalife Partners invests at the Seed, Series A, Series B, Late Stage stages.
- What is SCP Vitalife Partners's typical check size?
- SCP Vitalife Partners typically writes checks of $3M – $7M.
- What sectors does SCP Vitalife Partners focus on?
- SCP Vitalife Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is SCP Vitalife Partners located?
- SCP Vitalife Partners is headquartered in Tel Aviv, IL.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.